FRANKFURT, Feb 5 (Reuters) - Bayer said on Thursday its experimental blood thinner cut the risk of stroke recurrence by 26% ...

For many stroke survivors, recovery is derailed by painful muscle stiffness and involuntary spasms that limit movement, ...

The PSD-95 inhibitor also had a favorable safety profile in phase III trial ...

Expanded eligibility for advanced ischemic stroke therapies and the first detailed recommendations pediatric stroke care are ...

Overall, women who stuck most closely to an eating pattern resembling the Mediterranean diet had an 18% lower risk of any ...

The rationale behind the treatment is that, because genetic FXI deficiency has been linked with reduced risk of ischemic ...

Stroke patients treated intravenously with loberamisal, a novel neuroprotective medication, daily for 10 days and starting ...

Asundexian cut the risk of an additional stroke by 26% in a large Phase 3 trial without accompanying safety issues, boosting the commercial outlook for an emerging class of anti-clotting drugs.

Among adults with acute non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA) with planned ...

In infants and toddlers who had a stroke before birth or as a newborn (28 days or younger), a treatment that combined ...

Harford County woman Sarah Bochenick's stroke recovery story highlights how quick medical response can save lives and prevent ...

Rehabilitation from stroke has traditionally focused on improving the function of the most severely affected arm. But ...